The Risk of SARS-CoV-2 in Immunosuppressed IBD Patients

Area of Science:

• Gastroenterology
• Infectious Diseases
• Public Health

Background:

• Inflammatory Bowel Disease (IBD) patients may face unique risks from SARS-CoV-2 infection.
• Understanding COVID-19's impact on IBD is crucial for patient management and healthcare planning.
• The pandemic necessitated rapid adaptation of healthcare services for chronic conditions like IBD.

Purpose of the Study:

• To conduct a rapid review of SARS-CoV-2 infection risks, symptomatic COVID-19, and disease severity in IBD patients.
• To provide evidence-based guidance for managing IBD patients before and after infection.
• To highlight infection prevention strategies for IBD patients and healthcare providers during a pandemic.

Main Methods:

• Rapid review methodology was employed.
• Literature search focused on SARS-CoV-2, COVID-19, and IBD.
• Synthesis of findings to inform clinical recommendations.

Main Results:

• The review assessed the risk of SARS-CoV-2 infection and symptomatic COVID-19 in IBD patients.
• Severity of COVID-19 in this population was evaluated.
• Guidance for managing IBD patients at risk or post-infection was developed.

Conclusions:

• IBD patients require specific considerations regarding SARS-CoV-2 infection and COVID-19.
• Proactive management and infection control are essential for maintaining IBD care continuity.
• Telemedicine and reduced elective procedures are key strategies for safeguarding IBD patients and services.